Filing Flows › Health Care › Roivant Sciences (ROIV)
Roivant Sciences (ROIV) earnings and revenue breakdown
Latest: Q1 FY27 · 10-Q filed Aug 6, 2026 · Roivant Sciences (ROIV) Q1 FY27 earnings results →
Q1 FY27 Revenue down 34% year over year to $1.4M
Roivant Sciences made $1.4M in Q1 FY27 (-34% Y/Y). Operating margin n/m, net loss $291M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.4M in Q1 FY27, down 34% year over year and down 43% from the previous quarter.
Operating costs exceeded revenue by $366.0M, an operating margin of -25380.9%. Total costs grew 28% against a revenue fall of 34%. The fastest-growing cost line was Research & development (+32%). The quarter ended with a net loss of $290.6M, after a profit of $355.7M the previous quarter. Minority interests bore $100.8M of it: to shareholders the quarter was a loss of $189.8M. Non-operating items added $71.4M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$270.5M. Non-cash charges added back $600K of depreciation and amortization and $83.3M of share-based compensation. Working capital and other items used $63.8M. Capital expenditures of $419K exceeded it, leaving free cash flow of −$270.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 FY27 | 10-Q | Aug 6, 2026 | $1.4M | -34% | n/m | −$291M | −$271M |
| Q4 FY26 | 10-K | May 20, 2026 | $2.5M | -67% | n/m | $303M | −$164M |
| Q3 FY26 | 10-Q | Feb 6, 2026 | $2.0M | -78% | n/m | −$314M | −$196M |
| Q2 FY26 | 10-Q | Nov 10, 2025 | $1.6M | -65% | n/m | −$166M | −$186M |
| Q1 FY26 | 10-Q | Aug 11, 2025 | $2.2M | -73% | n/m | −$274M | −$204M |
| Q4 FY25 | 10-K | May 29, 2025 | $7.6M | -16% | n/m | −$252M | −$173M |
| Q3 FY25 | 10-Q | Feb 10, 2025 | $9.0M | -42% | n/m | $118M | −$207M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Roivant Sciences
Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or “Vants” to develop and commercialize our medicines and technologies.
In its own words, from its 10-K, filed May 20, 2026.
Roivant Sciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -34% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ROIV Roivant Sciences | Q1 FY27 | $1.4M | -34% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Roivant Sciences 10-Q on SEC EDGAR · CIK 1635088 · Pharmaceutical Preparations
More on ROIV
History
Every quarter: Q1 FY27 results · Q4 FY26 results · Q3 FY26 results · Q2 FY26 results · Q1 FY26 results · Q4 FY25 results · Q3 FY25 results